Skip to main content

The context you need, when you need it

When news breaks, you need to understand what actually matters — and what to do about it. At Vox, our mission to help you make sense of the world has never been more vital. But we can’t do it on our own.

We rely on readers like you to fund our journalism. Will you support our work and become a Vox Member today?

Join now

Nervana Raises Second Round This Year, as Silicon Valley Bets Big on Deep Learning

The DFJ-led round follows a series of deep learning investments, acquisitions and hires.

Vladgrin / Thinkstock

Nervana Systems, another player in the suddenly hot “deep learning” space, has closed its second round of capital in the last four months.

The San Diego startup said it raised $3.3 million in Series A funding led by DFJ, which comes on top of a $600,000 seed round in April.

DFJ’s Steve Jurvetson will take a seat on the company’s board as part of the latest investment. Allen & Co., AME Cloud Ventures and Fuel Capital also participated.

Deep learning is a form of artificial intelligence that researchers have credited with recent leaps in areas like speech recognition and image search. That has sparked growing interest in Silicon Valley, with Google, Facebook and Twitter making notable acquisitions or hires in recent months and various prominent players betting their own money on the space.

As Re/code explained in an earlier piece:

Deep learning is a form of machine learning in which researchers attempt to train computer algorithms to spot meaningful patterns by showing them lots of data, rather than trying to program in every rule about the world. Taking inspiration from the way neurons work in the human brain, deep learning uses layers of algorithms that successively recognize increasingly complex features — going from, say, edges to circles to an eye in an image.

Notably, these techniques have allowed researchers to train algorithms using unstructured data, where features haven’t been laboriously labeled by human beings ahead of time. It’s not a new concept, but recent refinements have resulted in significant advances over traditional AI approaches.

Nervana is aiming to distinguish itself in the nascent field by focusing on building hardware optimized for deep learning software — and vice versa.

“Traditionally, people write software algorithms that work well on the hardware that exists,” Nervana CEO Naveen Rao said in an interview. “We have the ability to co-develop and co-optimize them both. We’re innovating on the hardware and software sides.”

“We’re going to take things to the next level by applying technologies with an order of magnitude more performance and scale than we can do today.”

This article originally appeared on Recode.net.

More in Technology

Podcasts
Are humanoid robots all hype?Are humanoid robots all hype?
Podcast
Podcasts

AI is making them better — but they’re not going to be doing your chores anytime soon.

By Avishay Artsy and Sean Rameswaram
Future Perfect
The old tech that could help stop the next airborne pandemicThe old tech that could help stop the next airborne pandemic
Future Perfect

Glycol vapors, explained.

By Shayna Korol
Future Perfect
Elon Musk could lose his case against OpenAI — and still get what he wantsElon Musk could lose his case against OpenAI — and still get what he wants
Future Perfect

It’s not about who wins. It’s about the dirty laundry you air along the way.

By Sara Herschander
Life
Why banning kids from AI isn’t the answerWhy banning kids from AI isn’t the answer
Life

What kids really need in the age of artificial intelligence.

By Anna North
Culture
Anthropic owes authors $1.5B for pirating work — but the claims process is a Kafkaesque messAnthropic owes authors $1.5B for pirating work — but the claims process is a Kafkaesque mess
Culture

“Your AI monster ate all our work. Now you’re trying to pay us off with this piece of garbage that doesn’t work.”

By Constance Grady
Future Perfect
Some deaf children are hearing again because of a new gene therapySome deaf children are hearing again because of a new gene therapy
Future Perfect

A medical field that almost died is quietly fixing one disease at a time.

By Bryan Walsh